The CMS Reimbursement Controversy: A Mixed Bag for 340B Hospitals
Dr. Jonathan Harrison, PharmD | President & COO In 2022, a landmark decision by the Supreme Court shook the healthcare…
Ryanlyfe
Read More
Aug 25, 2023
Optimizing Mental Health Care: The Role of Clinical Psychiatric Pharmacists
By Dr. Ryan Paul | CEO Clinical psychiatric pharmacists play a crucial role in healthcare by specializing in the field…
Ryanlyfe
Read More
Aug 22, 2023
Usage vs Impact: Evaluating the Significance of Pharmacy-Focused Digital Health Tools
Dr. Ryan Paul | CEO In recent years, digital health tools have revolutionized the way healthcare services are delivered, including…
Ryanlyfe
Read More
Aug 15, 2023
A Powerful Movement for Global Public Health: The Connection Between Recovery and Mother Earth
By Dr. Dixie Brown and Dr. Ryan Paul Recovery from addiction is a complex and multifaceted journey that requires a…
Ryanlyfe
Read More
Aug 8, 2023
Zurzuvae’s Approval: A Personal Reflection on New Hope for Postpartum Depression
By Jonathon Harrison, PharmD | President and COO The recent FDA approval of Zurzuvae (zuranolone), the first-ever oral medication for…
Ryanlyfe
Read More
Aug 3, 2023
Community Health Series Part 2: Conference Confusion
By Robert Aanonsen, VP Business Development Immediately following the 2023 340B Summer Coalition Conference in Washington DC, articles were published…
Ryanlyfe
Read More
Jul 27, 2023
Becoming the Community’s Pharmacy of Choice: The Power of FQHCs
By James Waddell | VP, Sales In today’s healthcare landscape, access to affordable and comprehensive pharmacy services are crucial. Federally…
Ryanlyfe
Read More
Jul 25, 2023
Building Stronger Communities: A Holistic Approach to Ending HIV Transmission
A community-centered approach to eliminating HIV transmission involves empowering communities to take ownership of their own health and well-being. It…
Ryanlyfe
Read More
Jul 21, 2023
Community Health Series Part 1: Must We Take The Blue Pill?
By Robert Aanonsen, VP Business Development Lower reimbursement rates, increased manufacturer 340B pricing restrictions, monopolization of the PBM landscape and…